SEARCH

SEARCH BY CITATION

References

  • 1
    Moller S, Henriksen JH, Bendtsen F. Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009;44:90211.
  • 2
    Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S12131.
  • 3
    Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;60:12549.
  • 4
    Sherlock S. Vasodilatation associated with hepatocellular disease: relation to functional organ failure. Gut 1990;31:3657.
  • 5
    Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998;29:32841.
  • 6
    Moller S, Gulberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:13544.
  • 7
    Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: a systematic review. Resuscitation 2012;83:68491.
  • 8
    Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:57885.
  • 9
    Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197205.
  • 10
    Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011;96:E106572.
  • 11
    Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997;138:410922.
  • 12
    Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:26878.
  • 13
    Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001;22:1693711.
  • 14
    Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 2000;85:101620.
  • 15
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eng J Med 1998;339:3218.
  • 16
    Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:2346.
  • 17
    Blendis LM. Circulation in liver disease. Transpl Proc 1993;25:17413.
  • 18
    Henriksen JH. Systemic haemodynamic alterations in hepatic cirrhosis. Eur J Gastroenterol Hepatol 1991;3:70513.
  • 19
    Cillo U, Bassanello M, Lancerin F, Senzolo M, Burra P, Brolese A et al. Physiological and clinical implications of proANP(1-98) circulating levels in the perioperative phase of liver transplantation. Clin Chim Acta 2001;310:3948.
  • 20
    Kortgen A, Hetz H, Morgenthaler NG, Paxian G, Hitzler P, Krenn CG et al. Vasoactive mediators in patients with acute liver failure treated with albumin dialysis. Liver Int 2010;30:6346.
  • 21
    Gluud C. Serum testosterone concentrations in men with alcoholic cirrhosis: background for variation. Metabolism 1987;36:3738.
  • 22
    Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987;7:6604.
  • 23
    Zacho HD, Henriksen JH, Abrahamsen J. Chronic intestinal ischemia and splanchnic blood-flow: reference values and correlation with body-composition. World J Gastroenterol 2013;19:8828.
  • 24
    Kaltoft N, Hobolth L, Moller S. Non-invasive measurement of cardiac output by Finometer in patients with cirrhosis. Clin Physiol Funct Imaging 2010;30:2303.
  • 25
    Terzic D, Johansson-Fällgren AS, Ragnasson O, Goetze JP, Hammersten O. Evaluation of a sensitive copeptin assay for clinical measurement. Open Clin Biochem J 2012;5:2136.
  • 26
    Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:7258.
  • 27
    Nemutlu E, Zhang S, Juranic NO, Terzic A, Macura S, Dzeja P. 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases. Croat Med J 2012;53:52934.
  • 28
    Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:21926.
  • 29
    Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep 2012;9:24451.
  • 30
    Sola EMR, Rodriguez E, Barreto R, Cela R, Morales M, Ruiz P et al. Plasma copeptin levels are increased in cirrhosis and correlate with hyponatriemia and circulatory dysfunction. J Hepatol 2013;58:S229407.
  • 31
    Khaleghi M, Saleem U, Morgenthaler NG, Turner ST, Bergmann A, Struck J et al. Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension. Am J Hypertens 2009;22:42531.
  • 32
    Uusimaa P, Peuhkurinen S, Ylitalo A, Vuolteenaho O, Risteli J, Peuhkurinen K et al. Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. Acta Cardiol 2011;66:217.
  • 33
    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:18239.
  • 34
    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:1129.
  • 35
    Moreno JP, Grandclement E, Monnet E, Clerc B, Agin A, Cervoni JP et al. Plasma copeptin, a possible prognostic marker in cirrhosis. Liver Int 2013;33:84351.
  • 36
    Sola EMR, Elia C, Ruiz P, Rodriguez E, Barreto R, Cela R et al. Plasma copeptin as prognostic biomarker in patients with cirrhosis. Hepatology 2013;58:156A.
  • 37
    Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, Schulte J et al. Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med 2011;18:8519.
  • 38
    Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.
  • 39
    Lopez J, Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol 2002;221:192.
  • 40
    Zhou M, Chaudry IH, Wang P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am J Physiol Regul Integr Comp Physiol 2001;281:R65460.
  • 41
    Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y et al. Secretion of proadrenomedullin N-terminal 20 peptide from cultured neonatal rat cardiac cells. Life Sci 2001;69:23945.
  • 42
    Moller S, Iversen JS, Krag A, Bie P, Kjaer A, Bendtsen F. Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. Am J Physiol Gastrointest Liver Physiol 2010;299:G78490.
  • 43
    Angeli P, Jimenez W, Arroyo V, Mackenzie HS, Zhang PL, Claria J et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994;20:94854.